EyePoint Announces Strategic Prioritization
EyePoint announced that the Phase 3 LUCIA study of DURAVYU in wet AMD did not meet its primary non-inferiority endpoint, despite meeting key secondary endpoints on treatment burden, supplement-free rates, anatomic control, and safety. In response, the Board approved a strategic prioritization: a 53% workforce reduction, early conclusion of the pivotal wet AMD trials, and an estimated $30 million in annualized savings against roughly $9 million in one-time separation charges. The company is now pinning everything on DURAVYU in diabetic macular edema, with pivotal Phase 3 COMO and CAPRI topline data (551 patients enrolled) expected in Q4 2027.
Key figures
- Drug Name
- DURAVYU (vorolanib intravitreal insert)
- Phase Of Trial
- Phase 3
- Cash position
- $118 million as of September 30, 2026
- Dme data readout
- Q4 2027
- One time charges
- $9 million
- Workforce reduction
- 53%
- Dme trial enrollment
- 551
- Estimated annualized savings
- $30 million
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.